Accreditation/Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial SupportersThis activity is supported in part by educational grants from Abbott, Bayer HealthCare Pharmaceuticals Inc., Dendreon, Ferring Pharmaceuticals, Inc. and sanofi-aventis U.S.
5th Annual Interdisciplinary Prostate Cancer Congress™
Intercontinental New York Barclay
New York, NY
March 31, 2012
Prostate cancer is one of the most common cancers in men, affecting 1 out of every 6 men in the United States. Each year, it is diagnosed in 234,460 men and approximately 27,000 die as a result. Fortunately, continued progress has been made in the treatment of prostate cancer over the past 5 years, and improvements in both strategies and available therapeutic agents have increased survival rates for patients with prostate cancer.
Physicians’ Education Resource®, LLC (PER®) will host its Fifth Annual Interdisciplinary Prostate Cancer Congress (IPCC) at the New York Marriott East Side in New York City. This full-day continuing medical education (CME) activity entitled Novel Perspectives – Evolving Therapies and Advances In Standard of Care will address the differences that currently exist between urologists’, medical oncologists’, and radiation oncologists’ approaches to treating prostate cancer.
World-renowned thought leaders have been brought together to foster consensus about the best management of prostate cancer from the vantage point of interdisciplinary care teams. Topics of vital interest that will be include: hormonal therapies; imaging and staging; surgical advances; radiation therapies; and emerging multimodal therapies. The IPCC will include interactive cases designed to highlight multidisciplinary approaches for the management of prostate cancer with the overall goal of improving patient outcomes.
Urologists, medical oncologists, and radiation oncologists who treat patients with prostate cancer.
After completing this activity, participants should be able to:
- Recognize the advantages and disadvantages of screening and early detection in prostate cancer
- Review the current standard of care for patients with early-stage, localized, androgen-dependent, and hormone refractory and/or castrate-resistant metastatic prostate cancer and apply them to clinical practice
- Incorporate newly approved agents for maintaining bone health into therapeutic regimens for patients with prostate cancer
- Compare the similarities and disparities among current practice guidelines for prostate cancer management and select the guidelines for use in clinical practice
- Evaluate the efficacy and safety of emerging therapeutic strategies in prostate cancer and counsel patients on appropriate clinical trials
- Formulate an optimal interdisciplinary plan for the management of their patients with prostate cancer.
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.